National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health.
Johns Hopkins Bayview Medical Center.
Health Psychol. 2014 Jul;33(7):710-9. doi: 10.1037/hea0000087.
The objective of this study was to assess craving and mood related to opioid and cocaine use among asymptomatic hepatitis C virus (HCV)+ and HCV- methadone patients who have not started antiviral treatment.
In this 28-week prospective ecological momentary assessment (EMA) study, 114 methadone-maintained, heroin- and cocaine-abusing individuals reported from the field in real time on their mood, craving, exposure to drug-use triggers, and drug use via handheld computers.
Sixty-one percent were HCV+; none were overtly symptomatic or receiving HCV treatment. HCV status was not associated with age, sex, race, or past-30-day or lifetime heroin or cocaine use. In event-contingent EMA entries, HCV+ individuals more often attributed use to having been bored, worried, or sad; feeling uncomfortable; or others being critical of them compared with HCV- participants. In randomly prompted EMA entries, HCV+ participants reported significantly more exposure to drug-use triggers, including handling ≥$10, seeing cocaine or heroin, seeing someone being offered/use cocaine or heroin, being tempted to use cocaine, and wanting to see what would happen if they used just a little cocaine or heroin.
HCV+ individuals experienced more negative moods and more often cited these negative moods as causes for drug use. HCV+ individuals reported greater exposure to environmental drug-use triggers, but they did not more frequently cite these as causes for drug use. The EMA data reported here suggest that HCV+ intravenous drug users may experience more labile mood and more reactivity to mood than HCV- intravenous drug users. The reason for the difference is not clear, but HCV status may be relevant to tailoring of treatment.
本研究旨在评估未开始抗病毒治疗的无症状丙型肝炎病毒(HCV)+和 HCV-美沙酮患者的阿片类药物和可卡因使用相关的渴求感和情绪。
在这项为期 28 周的前瞻性生态瞬时评估(EMA)研究中,114 名美沙酮维持、海洛因和可卡因滥用者通过手持电脑实时从现场报告他们的情绪、渴求感、接触药物使用诱因和药物使用情况。
61%为 HCV+;均无明显症状或接受 HCV 治疗。HCV 状态与年龄、性别、种族或过去 30 天或终生海洛因或可卡因使用无关。在事件相关的 EMA 条目,HCV+个体更常归因于使用原因是无聊、担心或悲伤、感觉不舒服或他人批评他们与 HCV-参与者。在随机提示的 EMA 条目,HCV+参与者报告了更多的药物使用诱因暴露,包括处理≥$10、看到可卡因或海洛因、看到有人提供/使用可卡因或海洛因、受到诱惑使用可卡因以及想要知道如果他们使用一点可卡因或海洛因会发生什么。
HCV+个体经历了更多的负面情绪,并且更常将这些负面情绪归因于药物使用。HCV+个体报告了更多的环境药物使用诱因暴露,但他们并没有更频繁地将这些诱因作为药物使用的原因。这里报告的 EMA 数据表明,HCV+静脉药物使用者可能比 HCV-静脉药物使用者经历更不稳定的情绪和对情绪的更高反应性。原因尚不清楚,但 HCV 状态可能与治疗的调整有关。